TrialJCO global oncology2026

Pragmatic Clinical Trial Assessing Response to Neoadjuvant Docetaxel and Trastuzumab in Nigerian Women With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer (ARETTA).

Atara Ntekim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.